You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Inclisiran sodium - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for inclisiran sodium and what is the scope of patent protection?

Inclisiran sodium is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Inclisiran sodium has two hundred and twenty patent family members in thirty-three countries.

One supplier is listed for this compound.

Summary for inclisiran sodium
International Patents:220
US Patents:13
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 13
DailyMed Link:inclisiran sodium at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for inclisiran sodium
Generic Entry Date for inclisiran sodium*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for inclisiran sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Novartis PharmaceuticalsPhase 4
Novartis PharmaceuticalsPhase 2
The TIMI Study GroupPhase 3

See all inclisiran sodium clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for inclisiran sodium

US Patents and Regulatory Information for inclisiran sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis LEQVIO inclisiran sodium SOLUTION;SUBCUTANEOUS 214012-001 Dec 22, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Novartis LEQVIO inclisiran sodium SOLUTION;SUBCUTANEOUS 214012-001 Dec 22, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Novartis LEQVIO inclisiran sodium SOLUTION;SUBCUTANEOUS 214012-001 Dec 22, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
Novartis LEQVIO inclisiran sodium SOLUTION;SUBCUTANEOUS 214012-001 Dec 22, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for inclisiran sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis LEQVIO inclisiran sodium SOLUTION;SUBCUTANEOUS 214012-001 Dec 22, 2021 ⤷  Subscribe ⤷  Subscribe
Novartis LEQVIO inclisiran sodium SOLUTION;SUBCUTANEOUS 214012-001 Dec 22, 2021 ⤷  Subscribe ⤷  Subscribe
Novartis LEQVIO inclisiran sodium SOLUTION;SUBCUTANEOUS 214012-001 Dec 22, 2021 ⤷  Subscribe ⤷  Subscribe
Novartis LEQVIO inclisiran sodium SOLUTION;SUBCUTANEOUS 214012-001 Dec 22, 2021 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for inclisiran sodium

Country Patent Number Title Estimated Expiration
European Patent Office 2835429 Compositions et procédés d'inhibition d'expression du gène PCSK9 (Compositions and methods for inhibiting expression of the PCSK9 gene) ⤷  Subscribe
Australia 2013205519 MODIFIED IRNA AGENTS ⤷  Subscribe
Australia 2012202250 Modified iRNA agents ⤷  Subscribe
European Patent Office 4321177 CONJUGUÉS GLUCIDIQUES UTILISÉS COMME AGENTS D'ADMINISTRATION POUR DES OLIGONUCLÉOTIDES (CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES) ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for inclisiran sodium

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2929031 2021024 Norway ⤷  Subscribe PRODUCT NAME: INKLISIRAN; REG. NO/DATE: EU/1/20/1494 20201215
2929031 2190017-0 Sweden ⤷  Subscribe PRODUCT NAME: INCLISIRAN; REG. NO/DATE: EU/1/20/1494 20201210
2929031 CA 2021 00016 Denmark ⤷  Subscribe PRODUCT NAME: INCLISIRAN; REG. NO/DATE: EU/1/20/1494 20201210
2929031 PA2021510 Lithuania ⤷  Subscribe PRODUCT NAME: INKLISIRANAS; REGISTRATION NO/DATE: EU/1/20/1494 20201209
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Inclisiran sodium Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Inclisiran Sodium

Introduction

Inclisiran sodium, marketed as Leqvio, is a groundbreaking therapy for lowering low-density lipoprotein cholesterol (LDL-C) levels, particularly in patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). Here, we delve into the market dynamics and financial trajectory of this innovative drug.

Approval and Regulatory Landscape

Inclisiran has been approved in over 70 countries, including the EU and the USA, for the treatment of hypercholesterolemia in patients with ASCVD or HeFH. This widespread approval underscores its potential to address a significant unmet medical need globally[1][3][5].

Clinical Efficacy and Safety

Clinical trials, including those in the ORION series, have demonstrated inclisiran's consistent and remarkable LDL-C lowering effect, with reductions of approximately 50% when administered twice yearly. Long-term data show that inclisiran maintains its efficacy and safety profile beyond six years, making it a reliable option for long-term cholesterol management[1][3][5].

Market Need and Unmet Clinical Needs

Despite the availability of statins, many high-risk patients do not achieve optimal LDL-C levels. Inclisiran fills this gap by providing an effective and convenient treatment option. In China, for instance, the suboptimal LDL-C control rate among ASCVD patients is as low as 6.8-25.5%, making inclisiran a potentially game-changing therapy[1][4].

Pricing and Cost Considerations

Inclisiran comes with a significant price tag, with a wholesale acquisition cost (WAC) of $3,250 per injection, or $6,500 annually for the twice-yearly dosing regimen. This pricing has raised concerns among healthcare providers and payers, particularly in the US, where cost-efficacy analyses are crucial for reimbursement decisions[4].

Reimbursement and Access

In Europe, particularly in the UK, Novartis has negotiated discounts with health authorities to make inclisiran more accessible. The National Institute for Health and Care Excellence (NICE) has concluded that inclisiran is cost-effective for selected secondary prevention patients at the discounted price. However, in the US, commercial population health agreements with private health systems or payers are not anticipated due to reimbursement issues[4].

Financial Projections and Market Impact

Novartis anticipates significant revenue from inclisiran, despite the initial hurdles. The drug's inclusion in the company's late-stage development pipeline, with submission enabling readouts expected in 2024-2025, indicates a strong financial outlook. The VictORION clinical program, which includes over 30 trials and more than 60,000 patients, further solidifies inclisiran's market potential[2][3].

Adoption and Physician Sentiment

Physicians are optimistic about inclisiran's transformative potential in ASCVD prevention. The convenience of twice-yearly injections and the drug's efficacy in achieving LDL-C targets make it an attractive option. However, the high cost and lack of immediate outcomes data pose challenges to widespread adoption[4].

Competitive Landscape

Inclisiran competes with other LDL-C lowering therapies, including PCSK9 inhibitors. While PCSK9 inhibitors have solid clinical outcomes data, inclisiran's unique mechanism of action and dosing regimen set it apart. The higher cost of inclisiran compared to PCSK9 inhibitors is a point of contention, but its long-term efficacy and safety profile may justify the expense for many patients[4].

Global Reach and Clinical Trials

The VictORION program, which encompasses more than 30 clinical trials across over 50 countries, highlights inclisiran's global reach. Ongoing trials, such as the Phase 3 trial in Chinese and Asian patients, will further establish the drug's safety and efficacy in diverse populations[1][3].

Patient and Healthcare Provider Confidence

The long-term data demonstrating consistent LDL-C reduction with inclisiran has instilled confidence in both patients and healthcare providers. The predictable dosing regimen and minimal adverse events, such as injection site reactions, contribute to its appeal[3][5].

Future Outlook and Challenges

While inclisiran faces challenges related to cost and reimbursement, its long-term efficacy and safety make it a valuable addition to the arsenal against ASCVD. As outcomes data become available, the drug's cost-efficacy profile is likely to improve, enhancing its market position. Novartis's strategic efforts, including the 'buy-and-bill' model, aim to smooth the drug's path to market acceptance[4].

Key Takeaways

  • Clinical Efficacy: Inclisiran significantly reduces LDL-C levels with a convenient twice-yearly dosing regimen.
  • Market Need: Addresses the unmet need for effective LDL-C management in high-risk patients.
  • Pricing and Reimbursement: High cost poses challenges, but discounts and cost-efficacy analyses may improve accessibility.
  • Global Reach: Part of a large clinical program with trials in over 50 countries.
  • Physician Sentiment: Seen as transformative by physicians despite initial cost concerns.
  • Future Outlook: Long-term data and strategic market approaches are expected to enhance its market position.

FAQs

What is inclisiran sodium, and how does it work?

Inclisiran sodium, or Leqvio, is a small interfering RNA (siRNA) therapy that targets PCSK9 to lower LDL-C levels. It works by inhibiting the production of PCSK9, a protein that reduces the number of LDL receptors on the liver, thereby increasing LDL-C levels.

How often is inclisiran administered?

Inclisiran is administered via subcutaneous injection twice yearly.

What are the key benefits of inclisiran?

Inclisiran offers significant LDL-C reduction, a convenient dosing regimen, and long-term efficacy and safety.

Why is inclisiran considered expensive?

The wholesale acquisition cost (WAC) of inclisiran is $3,250 per injection, or $6,500 annually, which is higher than some other LDL-C lowering therapies.

Are there any ongoing clinical trials for inclisiran?

Yes, inclisiran is part of the VictORION clinical program, which includes over 30 trials and more than 60,000 patients worldwide.

Sources

  1. The clinical effects of inclisiran, a first-in-class LDL-C lowering ... - Lipid Journal
  2. Q4 2022 Results - Investor presentation - Novartis - Novartis
  3. Novartis presents new long-term Leqvio® (inclisiran) data ... - Novartis
  4. Pricey Inclisiran Is Rolling Out: a 'Buy-and-Bill' Model May Smooth ... - TCTMD
  5. Novartis presents new long-term Leqvio® (inclisiran) data ... - Novartis

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.